NB

Nathan Benaich

learning step-by-step

London, England

Invests in

Stages:

Locations:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Skills

Entrepreneurship
Research
Lifesciences
Molecular Biology
Start-ups
Business Development
Biotechnology
Data Analysis
Cell Biology
Science
Venture Capital
Strategy
Biochemistry
Angel Investing
Life Sciences

Education

Work Experience

  • General Partner 👨‍💻

    2019

    Adept AI (acq. Amazon), Allcyte (acq. Exscientia), Anagenex, Athenian, CellVoyant, ClipDrop (acq. Stability.ai/Jasper), Enveda Biosciences, Exscientia (NASDAQ: EXAI), Gandeeva Therapeutics, Gourmey, Graphcore (acq. SoftBank), Hedera Dx, Intenseye, Interloom, LabGenius, Delian AI (fka. Lambda Automata), Mission Barns, Modern Intelligence, Odyssey, Patina Systems, Poolside.ai, Profluent, Recursion Pharmaceuticals (NASDAQ: RXRX), Samaya.ai, Sereact, V7, Valence Discovery (acq. Recursion), ZOE, and several unannounced.

  • Co-author 🤓

    2018

    The definitive annual report on AI progress.

  • Scientist in Residence 👨‍🔬

    2017

  • Founder

    2021

    Rewriting the university spinout playbook.

Other

2013

  • Other things 👀

    2013

    > Author: State of AI Report, Guide to AI newsletter. > Founded: RAAIS, RAAIS Foundation, London.AI > Angel: Tractable, Niantic, LabGenius, Recursion (NASDAQ: RXRX), Synthesia, Crusoe Energy, Optimal Labs, PolyAI, KyraTV, The Engineering Company, Secondmind, ONI.bio, Kepler Computing, 20bn (acq. Qualcomm), Motion, Muon Space, Detail, Incident.io, Quench, Wayve, Synq, Kanna Health, Objective.inc, Contextual.ai, and Chroma. > Previously: Playfair Capital